Item 6 of the Schedule 13D is hereby amended and supplemented by the addition of the following: Voting Agreement On June 2, 2025, the Issuer, its directors and the members of the executive team of the Issuer, Beckley Psytech Limited and Apeiron entered into certain voting agreements in connection with the Acquisition. Pursuant to Apeiron's voting agreement with the Issuer (the "Voting Agreement"), Apeiron has agreed to vote (or cause to be voted) all of the Common Shares held by it in favor of certain matters set forth in the Voting Agreement, including to support (i) without limitation, shareholder approvals to approve the transactions contemplated by the share purchase agreement entered into in connection with the Acquisition and (ii) subject to certain conditions, any potential transaction that may be pursued by the Issuer to move the legal and tax domicile of the Issuer from the Netherlands (in respect of its corporate seat) and Germany (in respect of its tax domicile) to Delaware. The foregoing description of the Voting Agreement does not purport to be complete and is subject to and qualified in its entirety by reference to the full text of the Voting Agreement, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Shareholders Rights Agreement On June 2, 2025, Apeiron entered into a shareholders rights agreement with the Issuer (the "Rights Agreement"). Under the Rights Agreement, Apeiron will have the right, subject to certain requirements, to select a number of director designees equal to (i) two, for so long as Apeiron and its affiliates beneficially own no less than 12.5% of the equity securities of the Issuer (inclusive of Common Shares issued or issuable in connection with the exercise of options, warrants, rights, units or other securities) and (ii) one, for so long as Apeiron and its affiliates collectively beneficially own at least 7.5% but less than 12.5% of such Issuer equity securities. Apeiron also entered into a lock-up agreement (the "Lock-Up Agreement") on June 2, 2025 containing customary lock-up terms, pursuant to which Apeiron will, subject to certain exceptions, not transfer any equity securities of the Issuer for a certain specified period. At the expiration of such period, the lock-up restrictions will fall away in part on a monthly basis until the date that is twelve months following the expiration of such period. The foregoing description of the Rights Agreement and the Lock-Up Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Rights Agreement and the Lock-Up Agreement, copies of which are attached hereto as Exhibits 99.2 and 99.3, respectively, and are incorporated herein by reference. Registration Rights Agreement On June 2, 2025, the Issuer entered into a registration rights agreement with Apeiron, Mr. Angermayer and the PIPE Investors (the "Registration Rights Agreement") providing for certain registration rights with respect to Common Shares held by such holders from time to time. The Registration Rights Agreement requires the Issuer to file a registration statement under the Securities Act of 1933, as amended, providing for the resale of all or part of the registrable securities held by the parties thereto as promptly as practicable and use reasonable best efforts to cause such registration statement to be declared effective within the timelines specified therein, and thereafter to keep such registration statement effective for the periods specified therein. Apeiron will have customary demand rights that will require the Issuer to file registration statements registering its registrable securities. The Issuer has agreed to reasonably assist and cooperate, including by making management available for an electronic "road show" or other marketing efforts, in block trades and marketed or non-marketed underwritten shelf takedown offerings for sales by Apeiron with an offering price, in the aggregate, of at least $25 million. The Registration Rights Agreement also includes customary piggyback rights for Apeiron, subject to certain priority provisions. The Issuer has agreed to bear all registration expenses, including reasonable and documented fees of one counsel for all the selling shareholders, other than customary underwriting commissions or fees, regardless of whether a registration statement is filed or becomes effective. The Registration Rights Agreement also contains customary indemnity, exculpation and contribution obligations by the Issuer and the other parties to the Registration Rights Agreement. The foregoing description of the Registration Rights Agreement does not purport to be complete and is subject to and qualified in its entirety by reference to the full text of the Registration Rights Agreement, a copy of which is attached hereto as Exhibit 99.4 and is incorporated herein by reference. Option Grants On June 2, 2025, the Issuer granted to Mr. Angermayer in further consideration of his continued service as a consultant and other valuable consideration (i) an option to purchase 337,686 ordinary shares of the Issuer that will vest with respect to 131,698 shares subject to the option based on the Issuer's standard four year vesting schedule and with respect to 205,988 shares subject to the option based on the Issuer achieving asset value goals by December 31, 2026, and (ii) an option to purchase 292,500 shares that will vest based on the Issuer's standard four year vesting schedule. In addition, the options are subject to Mr. Angermayer entering into an amended consultancy agreement that provides for compliance with the Issuer's code of conduct, compliance program and the Voting Agreement. Other than as described herein, there are no contracts, arrangements, understandings or relationships among the Reporting Persons, or between the Reporting Persons and any other person, with respect to the securities of the Issuer.

Exhibit NoDescription 99.1 Voting Agreement, dated June 2, 2025, between Apeiron, the Issuer and Beckley Psytech Limited (incorporated by reference to Exhibit 10.2 to Form 8-K filed by the Issuer on June 2, 2025) 99.2 Shareholders Rights Agreement, dated June 2, 2025, between Apeiron and the Issuer (incorporated by reference to Exhibit 10.3 to Form 8-K filed by the Issuer on June 2, 2025) 99.3 Lock-Up Agreement, dated June 2, 2025, between Apeiron and the Issuer (incorporated by reference to Exhibit 10.4 to Form 8-K filed by the Issuer on June 2, 2025) 99.4 Registration Rights Agreement, dated June 2, 2025, between Apeiron, Christian Angermayer, the Issuer and certain shareholders named therein (incorporated by reference to Exhibit 10.8 to Form 8-K filed by the Issuer on June 2, 2025)